Predicting PK/PD advantages of modified activated coagulation factor VII molecules
Determining the impact of instrument variation and automated software algorithms on the thrombin generation test under hemophilia treatment conditions
Speaking Frankly to Young Adults with Hemophilia
Objective:   Few online resources are available for teens and young adults living with hemophilia. Frankly.net aspires to serve as a candid, trusted resource on real issues of concern for this age group. Our online forum…
Oral Care for People with Von Willebrand Disease: An Unmet Need
Objective: To assess the dental experiences of patients with von Willebrand disease for the purpose of developing guidelines for screening and dental management. Methods: A 13-question survey was…
Better Adherence to Prescribed Treatment Regimen is Associated with Less Chronic Pain among Adolescent and Young Adults with Moderate or Severe Hemophilia
Background/Aim: Little data exist, especially for adolescents and young adults (AYAs), about the relationship between adherence to prescribed hemophilia treatment regimens and chronic pain (CP). Methods: A…
Collaborative partnership helps resolve cultural barriers in patient receiving continuous infusion of factor (ACAT Protocol) in the home setting
Objective: When a surgical procedure is required in a patient with hemophilia, continuous infusion of factor (CIF) is a safe and effective alternative to bolus dosing.1-5 However, when cultural values collide with best practices…
Reduced Joint Range of Motion in Females with FVIII Deficiency
Objective: Our hypothesis was that females with FVIII deficiency enrolled in the Universal Data Collection (UDC) project have reduced mean joint range of motion (ROM) compared to historic controls from the Normal Joint Study…
Efficacy and safety of a novel rFIX (BAX326): phase III study in previously treated patients with severe or moderately severe hemophilia B undergoing surgical or other invasive procedures
Prospective Clinical Trial of a Novel Recombinant Factor IX in Previously Treated Patients
Objective: This prospective clinical trial was conducted to assess the safety, efficacy and PK of BAX326 (a novel recombinant FIX [rFIX] manufactured without the addition of any materials of human or animal origin, and with two…
Turoctocog alfa, a new B-domain truncated, recombinant factor VIII (rFVIII) developed by Novo Nordisk for the prevention and treatment of bleeding episodes in hemophilia A patients
Objective: Hemophilia A patients in the US benefit from safe, efficacious, and reliable factor VIII (FVIII) treatments. Novo Nordisk (Bagsværd, Denmark) has developed turoctocog alfa, the first new recombinant (r) FVIII in over a…